Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial

Autor: Reck, Martin, Schenker, Michael, Lee, Ki Hyeong, Provencio, Mariano, Nishio, Makoto, Lesniewski-Kmak, Krzysztof, Sangha, Randeep, Ahmed, Samreen, Raimbourg, Judith, Feeney, Kynan, Corre, Romain, Franke, Fabio Andre, Richardet, Eduardo, Penrod, John R., Yuan, Yong, Nathan, Faith E., Bhagavatheeswaran, Prabhu, DeRosa, Michael, Taylor, Fiona, Lawrance, Rachael, Brahmer, Julie
Zdroj: In European Journal of Cancer July 2019 116:137-147
Databáze: ScienceDirect
Externí odkaz: